Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz

• Status: Unknown status
• Trial end date: 2017-06-01

Summary

The purpose of this study is to determine whether calcium and vitamin D supplement can attenuate bone loss in HIV-infected-patients in Thailand who receive Tenofovir disoproxil fumarate.

• Phase: N/A

Details

• Lead Sponsor: Mahidol University
• Treatments: Calcium; Calcium Carbonate; Calcium, Dietary; Efavirenz; Emtricitabine; Ergocalciferols; Lamivudine; Tenofovir; Vitamin D; Vitamins